Objective: To observe the clinical efficacy of Chaifang oral liquid in the treatment for children with fever of acute upper respiratory infection(AURI). Method: Sixty-six qualified children with AURl were enrolled in this study and divided randomly into two groups: on the basis of conventional treatment

32 cases were treated with Chaifang oral liquid as Chinese medicine treatment group

34 cases were treated with ribavirin as western medicine controll group. With 3 day course of treatment

patients were observed for changes in temperature

primary clinical symptoms and signs before and after treatment for comparing efficacy. Result: ① Compared the temperature cooling time

the time of Chaifang oral liquid group was (2.8±1.3)days

the time of controlled group was (3.8±1.0)days

there is a statistical difference (P<0.01). The cooling start time (descended 0.5℃ by our standards)

that was (2.0±1.1)days in Chaifang oral liquid group

the time in controlled group was (2.8±1.1)days

there is a statistical difference (P<0.01). ② In Chaifang oral liquid treatment group

the total efficacy of pyrexia extinction was 84.4%. In controll group

the total efficacy of pyrexia extinction was 64.7%

there is a statistical difference within two groups (P<0.05). ③ After treatment

patients were observed changes in clinical symptoms and signs

such as pharyngalgia

cough and stuffy nose

the rates of symptom disappearance in Chaifang oral liquid treatment group were higher than those in the control group

there is a statistical difference (P<0.05) for the cough disappearance rate. Conclusion: Chaifang oral liquid is better than Western medicine for body temperature cooling and it can markedly improve clinical symptoms and signs. It is an effective prescription in the supplementary treatment for children with AURI. Thus

Chaifang oral liquid deserves popularization in clinical practice.